These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 16892899

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
    Szczepański T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ.
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):37-57. PubMed ID: 11987915
    [Abstract] [Full Text] [Related]

  • 3. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P, Mortuza FY, Hoffbrand AV, Foroni L.
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
    Chen JS, Hsiao CC, Sheen JM, Cheng CN.
    Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
    Campana D, Coustan-Smith E.
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):1-19. PubMed ID: 11987913
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Minimal residual disease as a surrogate marker for risk assignment to ALL patients.
    Cazzaniga G, Gaipa G, Rossi V, Biondi A.
    Rev Clin Exp Hematol; 2003 Sep; 7(3):292-323. PubMed ID: 15024971
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE.
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [Abstract] [Full Text] [Related]

  • 15. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G, Basso G, Biondi A, Campana D.
    Cytometry B Clin Cytom; 2013 Sep; 84(6):359-69. PubMed ID: 23757107
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Neale GA, Coustan-Smith E, Stow P, Pan Q, Chen X, Pui CH, Campana D.
    Leukemia; 2004 May; 18(5):934-8. PubMed ID: 15029212
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges.
    Izraeli S, Waldman D.
    Acta Haematol; 2004 May; 112(1-2):34-9. PubMed ID: 15179003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.